Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial.

IF 2.8 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Chris P Gale, Deborah Stocken, Ramesh Nadarajah, Suleman Aktaa, Catherine Reynolds, Rachael Gilberts, David B Brieger, Kathryn Carruthers, Derek P Chew, Shaun Goodman, Catherine Fernandez, Linda Sharples, Andrew T Yan, Keith A A Fox
{"title":"Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial.","authors":"Chris P Gale, Deborah Stocken, Ramesh Nadarajah, Suleman Aktaa, Catherine Reynolds, Rachael Gilberts, David B Brieger, Kathryn Carruthers, Derek P Chew, Shaun Goodman, Catherine Fernandez, Linda Sharples, Andrew T Yan, Keith A A Fox","doi":"10.1136/openhrt-2025-003213","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of risk stratification using the Global Registry of Acute Coronary Events (GRACE) Risk Score (GRS) for patients presenting to hospital with suspected non-ST elevation acute coronary syndrome (NSTEACS) according to troponin elevation is unknown.</p><p><strong>Methods: </strong>Post hoc analysis of a phase 3 parallel group cluster randomised controlled trial (UK GRACE Risk Score, UKGRIS) of adult patients presenting with suspected NSTEACS to 42 hospitals in England between 9 March 2017 and 30 December 2019, with hospitals randomised (1:1) to standard care or according to the GRS and associated guidelines. Coprimary outcome measures were use of guideline-recommended management and time to the composite of cardiovascular death, non-fatal myocardial infarction, new-onset heart failure hospitalisation or readmission for cardiovascular event at a minimum of 24 months follow-up.</p><p><strong>Results: </strong>A total of 3050 patients were randomised in UKGRIS, of whom 2602 had troponin elevation. The relative effect of GRS compared with standard care on the uptake of guideline-recommended care was greater for participants with troponin elevation compared with those without (relative OR 1.52, 95% CI 1.16 to 2.00, p<0.01). The time to the first composite event was not improved by the GRS among participants with (HR 0.89, 95% CI 0.70 to 1.14) or without troponin elevation (HR 1.14, 95% CI 0.79 to 1.64), with no interaction (relative HR 0.79, 95% CI 0.57 to 1.08, p=0.14 for interaction).</p><p><strong>Conclusions: </strong>For suspected NSTEACS, the effect of the GRS compared with standard care on uptake of recommended processes in those with elevated troponin was higher than in those without. However, this did not translate into a reduction in the composite primary or secondary outcomes at 24 months.</p><p><strong>Trial registration number: </strong>ISRCTN29731761.</p>","PeriodicalId":19505,"journal":{"name":"Open Heart","volume":"12 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Heart","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/openhrt-2025-003213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The effectiveness of risk stratification using the Global Registry of Acute Coronary Events (GRACE) Risk Score (GRS) for patients presenting to hospital with suspected non-ST elevation acute coronary syndrome (NSTEACS) according to troponin elevation is unknown.

Methods: Post hoc analysis of a phase 3 parallel group cluster randomised controlled trial (UK GRACE Risk Score, UKGRIS) of adult patients presenting with suspected NSTEACS to 42 hospitals in England between 9 March 2017 and 30 December 2019, with hospitals randomised (1:1) to standard care or according to the GRS and associated guidelines. Coprimary outcome measures were use of guideline-recommended management and time to the composite of cardiovascular death, non-fatal myocardial infarction, new-onset heart failure hospitalisation or readmission for cardiovascular event at a minimum of 24 months follow-up.

Results: A total of 3050 patients were randomised in UKGRIS, of whom 2602 had troponin elevation. The relative effect of GRS compared with standard care on the uptake of guideline-recommended care was greater for participants with troponin elevation compared with those without (relative OR 1.52, 95% CI 1.16 to 2.00, p<0.01). The time to the first composite event was not improved by the GRS among participants with (HR 0.89, 95% CI 0.70 to 1.14) or without troponin elevation (HR 1.14, 95% CI 0.79 to 1.64), with no interaction (relative HR 0.79, 95% CI 0.57 to 1.08, p=0.14 for interaction).

Conclusions: For suspected NSTEACS, the effect of the GRS compared with standard care on uptake of recommended processes in those with elevated troponin was higher than in those without. However, this did not translate into a reduction in the composite primary or secondary outcomes at 24 months.

Trial registration number: ISRCTN29731761.

根据肌钙蛋白升高的GRACE风险评分在非st段抬高急性冠脉综合征患者中的有效性:UKGRIS平行组群随机对照试验的事后分析。
背景:使用全球急性冠状动脉事件登记(GRACE)风险评分(GRS)对根据肌钙蛋白升高而就诊的疑似非st段抬高急性冠状动脉综合征(NSTEACS)患者进行风险分层的有效性尚不清楚。方法:对2017年3月9日至2019年12月30日期间英格兰42家医院疑似NSTEACS的成人患者进行的3期平行组群随机对照试验(UK GRACE Risk Score, UKGRIS)的后分析,医院随机(1:1)分配到标准治疗或根据GRS和相关指南。主要结局指标是在至少24个月的随访中使用指南推荐的治疗方法和心血管死亡、非致死性心肌梗死、新发心力衰竭住院或心血管事件再入院的时间。结果:共有3050例患者被随机纳入UKGRIS,其中2602例肌钙蛋白升高。对于肌钙蛋白升高的受试者,与标准治疗相比,GRS对指南推荐治疗摄取的相对影响大于没有肌钙蛋白升高的受试者(相对OR为1.52,95% CI为1.16至2.00)。结论:对于疑似NSTEACS,与标准治疗相比,GRS对肌钙蛋白升高的患者推荐过程摄取的影响高于没有肌钙蛋白升高的患者。然而,这并没有转化为24个月时综合主要或次要结局的降低。试验注册号:ISRCTN29731761。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Open Heart
Open Heart CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
3.70%
发文量
145
审稿时长
20 weeks
期刊介绍: Open Heart is an online-only, open access cardiology journal that aims to be “open” in many ways: open access (free access for all readers), open peer review (unblinded peer review) and open data (data sharing is encouraged). The goal is to ensure maximum transparency and maximum impact on research progress and patient care. The journal is dedicated to publishing high quality, peer reviewed medical research in all disciplines and therapeutic areas of cardiovascular medicine. Research is published across all study phases and designs, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Opinionated discussions on controversial topics are welcomed. Open Heart aims to operate a fast submission and review process with continuous publication online, to ensure timely, up-to-date research is available worldwide. The journal adheres to a rigorous and transparent peer review process, and all articles go through a statistical assessment to ensure robustness of the analyses. Open Heart is an official journal of the British Cardiovascular Society.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信